Patents Assigned to New Horizons Diagnostics
-
Patent number: 6395504Abstract: A method for the use of a phage associated lysing enzyme for the detecting the presence and determining the quantity of bacteria present in or on a wide variety of substances is described. The total concentration of microbes is determined by adding or incorporating a phage associated lytic agent to a disposable test system device with the luminescent reagents luciferin and luciferase, and introducing the disposable test system into a luminometer that can read the luminescence. Other systems can be used with the lytic enzymes for the quantitative and qualitative determination for the presence of bacteria.Type: GrantFiled: September 1, 2000Date of Patent: May 28, 2002Assignee: New Horizons Diagnostics Corp.Inventor: David Trudil
-
Patent number: 6326002Abstract: The present invention discloses a method for treating Streptococcal infections of the upper respiratory tract, comprising administering an effective amount of a lysin enzyme produced by group C Streptococcal bacteria infected with a C1 bacteriophage specific for the bacteria to a mouth, throat, or nasal passage of a mammal, the method providing a concentration of from about 100 to 500,000 active enzyme units per milliliter of fluid in the environment of said nasal or oral passages.Type: GrantFiled: September 28, 2000Date of Patent: December 4, 2001Assignee: New Horizons Diagnostics CorporationInventors: Vincent Fischetti, Lawrence Loomis
-
Patent number: 6277399Abstract: A composition for treatment of bacterial infections of burns and wounds of the skin comprises an effective amount of at least one lytic enzyme produced by a bacteria infected with a bacteriophage specific for said bacteria, and a carrier for delivering said at least one lytic enzyme to the skin. The carrier may be, but is not limited to, a liquid solution applied to a bandage.Type: GrantFiled: September 28, 2000Date of Patent: August 21, 2001Assignee: New Horizon Diagnostics CorporationInventors: Vincent Fischetti, Lawrence Loomis
-
Patent number: 6254866Abstract: A method for treatment of bacterial infections of the digestive tract is disclosed which comprises administering a lytic enzyme specific for the infecting bacteria. The lytic enzyme is preferably in a carrier for delivering said lytic enzyme. The bacteria to be treated is selected from the group consisting of Listeria, Salmonella, E. coli, Campylobacter, and combinations thereof. The carrier for delivering at least one lytic enzyme to the digestive tract is selected from the group consisting of suppository enemas, syrups, or enteric coated pills.Type: GrantFiled: September 1, 2000Date of Patent: July 3, 2001Assignee: New Horizons Diagnostics CorporationInventors: Vincent Fischetti, Lawrence Loomis
-
Patent number: 6238661Abstract: Compositions and methods for the prophylactic and therapeutic treatment of bacterial infections are disclosed which comprise administering to an individual an effective amount of a composition comprising an effective amount of lytic enzyme and a carrier for delivering the lytic enzyme. This method and composition can be used for the treatment of upper respiratory infections, skin infections, wounds, burns, vaginal infections, eye infections, intestinal disorders and dental problems.Type: GrantFiled: April 18, 2000Date of Patent: May 29, 2001Assignee: New Horizons Diagnostics Corp.Inventors: Vincent Fischetti, Lawrence Loomis
-
Patent number: 6056954Abstract: A method for the prophylactic and therapeutic treatment of bacterial infections is disclosed which comprises the treatment of an individual with an effective amount of a lytic enzyme composition specific for the infecting bacteria, with the lytic enzyme comprising an effective amount of lytic enzyme, wherein the lytic enzyme is in an environment having a pH which allows for activity of said lytic enzyme; and a carrier for delivering said lytic enzyme. This method, and composition can be used for the treatment of upper respiratory infections, skin infections, wounds, and burns, vaginal infections, eye infections, intestinal disorders and dental problems.Type: GrantFiled: September 14, 1999Date of Patent: May 2, 2000Assignee: New Horizons Diagnostics CorpInventors: Vincent A. Fischetti, Lawrence Loomis
-
Patent number: 6017528Abstract: The present invention relates to compositions containing Group C streptococcal phage associated lysin enzyme for the prophylactic and therapeutic treatment of Streptococcal infections, including the infection commonly known as strep throat. Methods for therapeutically and prophylactically treating such infections also are described.Type: GrantFiled: February 25, 1999Date of Patent: January 25, 2000Assignee: New Horizons DiagnosticsInventors: Vincent Fischetti, Lawrence Loomis
-
Patent number: 5997862Abstract: The present invention relates to an oral delivery system containing a group c streptococcal phage associated lysin enzyme for the prophylactic and therapeutic treatment of Streptococcal A throat infections, commonly known as strep throat.Type: GrantFiled: October 31, 1997Date of Patent: December 7, 1999Assignee: New Horizons Diagnostics CorporationInventors: Vincent Fischetti, Lawrence Loomis
-
Patent number: 5985271Abstract: The present invention relates to an oral delivery system containing a group c streptococcal phage associated lysin enzyme for the prophylactic and therapeutic treatment of Streptococcal A throat infections, commonly known as strep throat.Type: GrantFiled: February 25, 1999Date of Patent: November 16, 1999Assignee: New Horizons Diagnostics Corp.Inventors: Vincent Fischetti, Lawrence Loomis
-
Patent number: 5736351Abstract: A method and device for determining the presence and concentration of total microbial contamination or the presence and concentration of a specific microbial species on a surface is described. The method consists of a means of a collection device and fluid for removing the microbes from the surface and suspending them in a fluid phase. An aliquot of the fluid phase is introduced into a disposable test ticket which allows filtration of the sample to remove extraneous substances including somatic cells, and concentration of the microbes. The total concentration of microbes is determined by adding a somatic and bacterial releasing reagent to a disposable test device which comprises a membrane containing the luminescent reagents luciferin and luciferase, and introducing the disposable test device into a luminometer that can read the luminescence from the underside.Type: GrantFiled: January 15, 1997Date of Patent: April 7, 1998Assignee: New Horizons Diagnostics CorporationInventors: C. David Miller, Lawrence Loomis
-
Patent number: 5624810Abstract: A method for determining the presence and concentration of total microbial contamination or the presence and concentration of a specific microbial species on a surface is described. The method consists of a means of a collection device and fluid for removing the microbes from the surface and suspending them in a fluid phase. An aliquot of the fluid phase is introduced into a disposable test device which allows filtration of the sample to remove extraneous substances including somatic cells, and concentration of the microbes. The total concentration of microbes is determined by adding a bacterial releasing reagent and a luminescent reagent to the disposable test device and introducing the disposable test device into a luminometer that can read the luminescence from the side wall.Type: GrantFiled: January 9, 1995Date of Patent: April 29, 1997Assignee: New Horizons Diagnostics Corp.Inventors: C. David Miller, Lawrence Loomis
-
Patent number: 5604109Abstract: The present invention relates to the rapid detection of Group A streptococci in clinical specimens, through the enzymatic digestion by a semi-purified Group C streptococcal phage associated lysin enzyme and the identification of the released antigens, through the reaction of a labelled ligand and its respective antigen or receptor. The labelled ligand can be included during the digestion of the bacteria, enabling the total assay time to be less than five minutes. The lysin enzyme is stabilized and can be lyophilized for in situ reconstitution.Type: GrantFiled: September 13, 1994Date of Patent: February 18, 1997Assignee: New Horizons Diagnostics CorporationInventors: Vincent A. Fischetti, David Bernstein
-
Patent number: 5393658Abstract: An assay is provided in which a target ligand is detected in a biological specimen. The method involves treating the target ligand with detergent and then binding the treated ligand to a particle by means of a capturing substance on the particle, thereby forming a complex. The complex is then applied to a porous membrane having a charge similar to that of a glass fiber filter in order to immobilize the complex in the porous membrane. The pore size of the membrane is substantially larger than the size of the complex such that the immobilization of the complex is substantially accomplished by means of the attraction of the complex to the charge of the porous membrane, and not as a function of the pore size of the membrane. Thereafter, the presence of the complex in the porous membrane is detected.Type: GrantFiled: April 6, 1993Date of Patent: February 28, 1995Assignee: New Horizons Diagnostics CorporationInventor: Duane A. Olsen
-
Patent number: 5169789Abstract: A device and method for a self contained solid phase immunodiffusion assay. The device is comprised of a sample collector, and a pre-fabricated laminate which can be used in many different forms. For example, the same collector and laminate can be used with a tube having compartmentalized reagents. The seals can be broken through pressure on the sample collector. The sample collector is pushed through the seals, mixed with reagent, and then pushed into a ligand receptor reaction area which is part of the laminate. The tip of the sample collector contacts diffusable or porous membranes or filters and transfers the reactants to a capture membrane wherein a ligand receptor reaction can be examined by the naked eye or otherwise.Type: GrantFiled: December 27, 1991Date of Patent: December 8, 1992Assignee: New Horizons Diagnostics CorporationInventor: David Bernstein
-
Patent number: 4770853Abstract: A device for a self contained solid phase immunodiffusion assay. The device is comprised of a sample collector, a tube with compartmentalized reagents and a ligand receptor capture membrane filter area. The seals can be broken through pressure on the sample collector. The sample collector is pushed through the seals, mixed with reagent, and then pushed into a ligand receptor reaction area wherein the tip of the sample collector contacts diffusable membranes or filters and transfers the reactants to a capture membrane wherein a ligand receptor reaction can be visualized by the naked eye.Type: GrantFiled: December 3, 1986Date of Patent: September 13, 1988Assignee: New Horizons Diagnostics CorporationInventor: David Bernstein
-
Patent number: 4704355Abstract: An assay utilizing receptor or antibody sensitized liposome particles which have ATP encapsulated therein. The ATP is released by lysing the liposomes, and detected by means of luciferin-luciferase reagent and a luminometer. The assay provides a very sensitive process for detecting the presence of analytes such as antigens and DNA probes.Type: GrantFiled: March 27, 1985Date of Patent: November 3, 1987Assignee: New Horizons Diagnostics CorporationInventor: David Bernstein